## Diagnosis of fatty liver disease

European Journal of Gastroenterology and Hepatology 15, 539-543

DOI: 10.1097/01.meg.0000059112.41030.2e

Citation Report

#	Article	IF	CITATIONS
1	Can an increase of body mass index by 1?kg/m2 be a risk for obesity-related diseases?. Journal of Gastroenterology, 2003, 38, 1022-1023.	2.3	3
2	Hypertransaminasemia and severe hepatic steatosis without inflammation. A case report. Annals of Hepatology, 2003, 2, 183-185.	0.6	2
3	The Prevalence of Autoantibodies and Autoimmune Hepatitis in Patients with Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2004, 99, 1316-1320.	0.2	202
4	The Role of Ultrasound in the Diagnosis of Hepatic Steatosis in Morbidly Obese Patients. Obesity Surgery, 2004, 14, 635-637.	1.1	259
5	Valproate therapy and nonalcoholic fatty liver disease. Annals of Neurology, 2004, 55, 729-732.	2.8	89
6	Clinical impact of antibody formation to botulinum toxin A in children. Annals of Neurology, 2004, 55, 732-735.	2.8	59
7	Beneficial Effects of Tumor Necrosis Factor-alpha Inhibition by Pentoxifylline on Clinical, Biochemical, and Metabolic Parameters of Patients with Nonalcoholic Steatohepatitis. American Journal of Gastroenterology, 2004, 99, 1946-1952.	0.2	188
8	Non-alcoholic steatohepatitis: review of a growing medical problem. European Journal of Internal Medicine, 2004, 15, 10-21.	1.0	80
9	Mitochondrial injury in the pathogenesis of antiretroviral-induced hepatic steatosis and lactic acidemia. Mitochondrion, 2004, 4, 95-109.	1.6	27
10	Bibliography Current World Literature. Current Opinion in Gastroenterology, 2004, 20, 288-307.	1.0	O
11	Role of liver biopsy in the assessment of non-alcoholic fatty liver disease. European Journal of Gastroenterology and Hepatology, 2004, 16, 1107-1115.	0.8	26
12	Recent concepts in non-alcoholic fatty liver disease. Diabetic Medicine, 2005, 22, 1129-1133.	1.2	262
13	Liver echogenicity: Relation to systemic blood pressure and other components of the metabolic syndrome. Ultrasound in Medicine and Biology, 2005, 31, 293-299.	0.7	7
14	The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: A retrospective observational study. BMC Gastroenterology, 2005, 5, 14.	0.8	75
15	Nonalcoholic fatty liver disease. Cmaj, 2005, 172, 899-905.	0.9	512
16	Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care, 2005, 28, 1518-1523.	<b>4.</b> 3	41
17	Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance. Metabolic Syndrome and Related Disorders, 2005, 3, 316-327.	0.5	3
18	Fat in the liver and insulin resistance. Annals of Medicine, 2005, 37, 347-356.	1.5	235

#	Article	IF	CITATIONS
19	Association of Cardiorespiratory Fitness, Body Mass Index, and Waist Circumference to Nonalcoholic Fatty Liver Disease. Gastroenterology, 2006, 130, 2023-2030.	0.6	229
20	Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 335-348.	2.9	330
21	Protocol for measurement of liver fat by computed tomography. Journal of Applied Physiology, 2006, 100, 864-868.	1.2	69
22	Correlation of ultrasound attenuation and histopathological parameters of the liver in chronic diffuse liver diseases. European Journal of Gastroenterology and Hepatology, 2006, 18, 37-42.	0.8	23
23	Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anti-Cancer Drugs, 2006, 17, 709-713.	0.7	34
24	Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, 413-427.	0.9	214
25	Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver International, 2006, 26, 856-863.	1.9	230
26	Review article: drug therapy for non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 207-215.	1.9	53
27	A Comparison of Wedge and Needle Hepatic Biopsy in Open Bariatric Surgery. Obesity Surgery, 2006, 16, 178-182.	1.1	32
28	Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology, 2006, 43, S99-S112.	3.6	2,116
29	Hepatic lipid accumulation in healthy subjects: A comparative study using spectral fat-selective MRI and volume-localized1H-MR spectroscopy. Magnetic Resonance in Medicine, 2006, 55, 913-917.	1.9	146
30	Low-carbohydrate diet induced reduction of hepatic lipid content observed with a rapid non-invasive MRI technique. British Journal of Radiology, 2006, 79, 712-715.	1.0	42
31	Fatty Liver: Imaging Patterns and Pitfalls. Radiographics, 2006, 26, 1637-1653.	1.4	362
32	Treatment of non-alcoholic fatty liver disease. Postgraduate Medical Journal, 2006, 82, 315-322.	0.9	223
34	Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. Endocrine Research, 2007, 32, 59-69.	0.6	18
35	Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence. Gut, 2007, 56, 1-113.	6.1	120
36	Non-Alcoholic Fatty Liver Disease in Children. Current Nutrition and Food Science, 2007, 3, 141-144.	0.3	0
37	Interobserver and Intraobserver Variability in the Sonographic Assessment of Fatty Liver. American Journal of Roentgenology, 2007, 189, W320-W323.	1.0	384

#	Article	IF	Citations
38	Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opinion on Therapeutic Targets, 2007, 11, 1231-1249.	1.5	45
39	Nonalcoholic Fatty Liver Disease. Annals of Epidemiology, 2007, 17, 863-869.	0.9	262
40	Imaging of hepatic steatosis and fatty sparing. European Journal of Radiology, 2007, 61, 33-43.	1.2	110
41	Non-invasive quantification of hepatic fat fraction by fast 1.0, 1.5 and 3.0T MR imaging. European Journal of Radiology, 2007, 62, 416-422.	1.2	52
42	Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Journal of Hepatology, 2007, 47, 412-417.	1.8	180
43	[701] PENTOXIFYLLINE FOR TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): A RANDOMIZED, PLACEBO-CONTROLLED STUDY. Journal of Hepatology, 2007, 46, S264-S265.	1.8	2
44	Non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2007, 42, 1023-1030.	0.6	45
46	Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance. Medical Clinics of North America, 2007, 91, 1125-1149.	1.1	136
47	Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease. Gastroenterology, 2007, 132, 2191-2207.	0.6	284
48	Non Alcoholic Fatty Liver Disease- Is It Always Benign?. Journal of Bangladesh College of Physicians & Surgeons, 2007, 25, 144-152.	0.0	2
49	Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. Annals of Hepatology, 2007, 6, 255-261.	0.6	14
50	Evaluation of hepatic steatosis by ultrasound in patients with chronic hepatitis C virus infection. Liver International, 2007, 27, 748-757.	1.9	37
51	Biermer's Anemia: A New Cause of Cholestasis and Hepatic Steatosis?. Digestive Diseases and Sciences, 2007, 52, 3366-3368.	1.1	3
52	State and trait anxiety and depression in patients affected by gastrointestinal diseases: psychometric evaluation of 1641 patients referred to an internal medicine outpatient setting. International Journal of Clinical Practice, 2008, 62, 1063-1069.	0.8	120
53	Serum retinolâ€binding protein 4 levels are elevated in nonâ€alcoholic fatty liver disease. Clinical Endocrinology, 2008, 68, 555-560.	1.2	81
54	Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism: Clinical and Experimental, 2008, 57, 569-576.	1.5	134
55	Hepatic steatosis rather than visceral adiposity is more closely associated with insulin resistance in the early stage of obesity. Metabolism: Clinical and Experimental, 2008, 57, 980-985.	1.5	35
56	Probable NAFLD, by ALT levels, and diabetes among Filipino-American Women. Diabetes Research and Clinical Practice, 2008, 79, 133-140.	1.1	20

#	Article	IF	Citations
57	Ultrasonographic diagnosis of nonalcoholic steatohepatitis based on the quantitative evaluation of the ultrasound beam behavior into the liver., $2008$ ,,.		4
58	Statistical relevance of ultrasonographic criteria in the assessment of diffuse liver disease in dogs and cats. American Journal of Veterinary Research, 2008, 69, 212-221.	0.3	74
59	Intimaâ€Media Thickness of Carotid Artery and Susceptibility to Atherosclerosis in Obese Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2008, 47, 68-75.	0.9	70
60	3: Abnormal Liver Tests. , 2008, , .		O
61	Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Annals of Hepatology, 2008, 7, 212-220.	0.6	91
62	The Relation Between Non-Alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease in Koreans. American Journal of Gastroenterology, 2009, 104, 1953-1960.	0.2	117
63	Computer-Assisted Ultrasound Analysis of Liver Echogenicity in Obese and Normal-Weight Children. American Journal of Roentgenology, 2009, 192, W201-W205.	1.0	23
65	Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut, 2009, 58, 1419-1425.	6.1	68
66	Nonviral Hepatitis. Journal of Pharmacy Practice, 2009, 22, 388-404.	0.5	5
67	Serum Adipocyte Fatty Acid-Binding Protein Levels Are Associated With Nonalcoholic Fatty Liver Disease in Type 2 Diabetic Patients. Diabetes Care, 2009, 32, 147-152.	4.3	61
68	Review: Current status of therapy in nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology, 2009, 2, 29-43.	1.4	11
69	Abdominal complications of chemotherapy in pediatric malignancies: imaging findings. Clinical Imaging, 2009, 33, 253-260.	0.8	17
70	Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatric Diabetes, 2009, 10, 5-13.	1.2	86
71	Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabetic Medicine, 2009, 26, 1235-1241.	1.2	50
72	Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment. Epilepsy Research, 2009, 86, 42-47.	0.8	83
73	Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods. European Radiology, 2009, 19, 2033-2040.	2.3	95
74	Histopathology of Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2009, 13, 533-544.	1.0	116
75	Diagnostic Value of a Computerized Hepatorenal Index for Sonographic Quantification of Liver Steatosis. American Journal of Roentgenology, 2009, 192, 909-914.	1.0	222

#	Article	IF	CITATIONS
76	Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 T. Radiology, 2009, 251, 67-76.	3.6	287
77	Association between nonalcoholic fatty liver disease and carotid intima-media thickness according to the presence of metabolic syndrome. Atherosclerosis, 2009, 204, 521-525.	0.4	123
78	Methods for assessing intrahepatic fat content and steatosis. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 474-481.	1.3	42
79	Imaging of Nonalcoholic Steatohepatitis: Advantages and Pitfalls of Ultrasonography and Computed Tomography. Internal Medicine, 2009, 48, 739-746.	0.3	71
80	Quantitative Assessment of Intrahepatic Lipids Using Fat-Selective Imaging With Spectral-Spatial Excitation and In-/Opposed-Phase Gradient Echo Imaging Techniques Within a Study Population of Extremely Obese Patients. Investigative Radiology, 2010, 45, 484-490.	3.5	14
82	Hepatic artery resistance in children with obesity and fatty liver. Indian Journal of Pediatrics, 2010, 77, 407-411.	0.3	9
84	Pearls and Pitfalls in Hepatic Ultrasonography. Ultrasound Quarterly, 2010, 26, 17-25.	0.3	17
86	The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. Journal of Hepatology, 2010, 53, 335-338.	1.8	146
87	Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. Fertility and Sterility, 2010, 93, 1220-1226.	0.5	40
88	Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics, 2010, 57, 85-140.	0.5	40
89	Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification. Hepatology Research, 2010, 40, 399-406.	1.8	30
90	Fatty liver and its clinical management in obese adolescents. Endocrinolog $ ilde{A}$ a Y Nutrici $ ilde{A}$ 3n (English) Tj ETQq $1\ 1\ 0$	0.784314	rgBT /Overlo
91	Management of chronic liver disease by general practitioners in Southern Italy: Unmet educational needs. Digestive and Liver Disease, 2011, 43, 736-741.	0.4	17
93	Diffuse parenchymal liver disease. , 2011, , 104-119.		0
94	Hyperinsulinemia and the Development of Nonalcoholic Fatty Liver Disease in Nondiabetic Adults. American Journal of Medicine, 2011, 124, 69-76.	0.6	53
96	The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: Intra- and interobserver variability and comparison with magnetic resonance spectroscopy. Clinical Radiology, 2011, 66, 434-439.	0.5	30
97	Fade-out sign on hepatic tissue harmonic compound sonography: A value as a new sign in the diagnosis of fatty liver. European Journal of Radiology, 2011, 80, e258-e262.	1.2	3
98	Association among Histopathology, Clinical Manifestation, and Ultrasonographic Grades in Pediatric Non-alcoholic Fatty Liver Disease. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2011, 57, 158.	0.2	5

#	Article	IF	CITATIONS
99	Contribuição da ultrassonografia para o diagnóstico das alterações histopatológicas presentes na hepatite C crÃ′nica, com ênfase na esteatose hepática: Parte I. Radiologia Brasileira, 2011, 44, 141-146.	0.3	6
100	Comparison of 1H MR Spectroscopy, 3-point DIXON, and Multi-echo Gradient Echo for Measuring Hepatic Fat Fraction. Magnetic Resonance in Medical Sciences, 2011, 10, 41-48.	1.1	20
101	Non-alcoholic fatty liver disease (NAFLD) and immune response. Journal of the Institute of Medicine, 2011, 32, 43-53.	0.1	2
102	Systematic review: the diagnosis and staging of nonâ€alcoholic fatty liver disease and nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2011, 33, 525-540.	1.9	254
103	Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese. Clinical Endocrinology, 2011, 75, 240-246.	1.2	77
104	Diet prescription for nonâ€alcoholic fatty liver disease: Is it worth the effort? A systematic review. Nutrition and Dietetics, 2011, 68, 33-40.	0.9	1
105	Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension. International Journal of Obesity, 2011, 35, 270-278.	1.6	45
106	Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial. Metabolism: Clinical and Experimental, 2011, 60, 1278-1284.	1.5	67
107	Simultaneous assessment of liver volume and whole liver fat content: a step towards one-stop shop preoperative MRI protocol. European Radiology, 2011, 21, 301-309.	2.3	20
108	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 511-523.	1.4	116
109	Liver methylene fraction by dual―and tripleâ€echo gradientâ€echo imaging at 3.0T: Correlation with proton MR spectroscopy and estimation of robustness after SPIO administration. Journal of Magnetic Resonance Imaging, 2011, 33, 119-127.	1.9	12
110	Reproducibility of MRIâ€determined proton density fat fraction across two different MR scanner platforms. Journal of Magnetic Resonance Imaging, 2011, 34, 928-934.	1.9	130
111	Estimation of Hepatic Proton-Density Fat Fraction by Using MR Imaging at 3.0 T. Radiology, 2011, 258, 749-759.	3.6	259
113	Quantification of liver fat in mice: comparing dual-echo Dixon imaging, chemical shift imaging, and 1H-MR spectroscopy. Journal of Lipid Research, 2011, 52, 1847-1855.	2.0	30
114	Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterology, 2011, 2011, 1-11.	1.5	113
115	Carotid Intima-Media Thickness Is Increased Not Only in Non-Alcoholic Fatty Liver Disease Patients but Also in Alcoholic Fatty Liver Patients. Digestion, 2011, 84, 149-155.	1.2	17
116	Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care, 2011, 34, 1139-1144.	4.3	332
117	Detection of Hepatic Steatosis on Contrast-Enhanced CT Images: Diagnostic Accuracy of Identification of Areas of Presumed Focal Fatty Sparing. American Journal of Roentgenology, 2012, 199, 44-47.	1.0	64

#	Article	IF	CITATIONS
118	Features of Hepatic and Skeletal Muscle Insulin Resistance Unique to Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1663-1672.	1.8	76
119	Methodologies for Investigating Natural Medicines for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). Current Pharmaceutical Biotechnology, 2012, 13, 278-291.	0.9	24
120	Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 164-171.	0.8	39
122	Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary and Pancreatic Diseases International, 2012, 11, 513-520.	0.6	32
123	A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterology, 2012, 12, 69.	0.8	129
124	Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?. Cardiovascular Diabetology, 2012, 11, 61.	2.7	37
125	Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight/obese Egyptian children. European Journal of Radiology, 2012, 81, 3120-3123.	1.2	35
126	Frequency of non-alcoholic fatty liver disease in overweight/obese children and adults: Clinical, sonographic picture and biochemical assessment. Journal of Genetic Engineering and Biotechnology, 2012, 10, 221-227.	1.5	14
127	Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine, 2012, 42, 423-429.	1.1	91
128	Liverâ€vessel cancellation artifact on inâ€phase and outâ€ofâ€phase MRI imaging: A sign of ultraâ€high liver fat content. Journal of Magnetic Resonance Imaging, 2012, 35, 1112-1118.	1.9	4
129	Automated liver sampling using a gradient dualâ€echo Dixonâ€based technique. Magnetic Resonance in Medicine, 2012, 67, 1469-1477.	1.9	9
130	Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. Journal of Gastroenterology, 2012, 47, 696-703.	2.3	49
131	Clinical Predictors of Different Grades of Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2012, 22, 248-252.	1.1	15
132	A gene variant of $\langle i \rangle$ PNPLA3 $\langle i \rangle$ , but not of $\langle i \rangle$ APOC3 $\langle i \rangle$ , is associated with histological parameters of NAFLD in an obese population. Obesity, 2013, 21, 2138-2145.	1.5	57
133	Complications of oncologic therapy in the abdomen and pelvis: a review. Abdominal Imaging, 2013, 38, 1-21.	2.0	20
134	Polycystic ovary syndrome and nonalcoholic fatty liver in obese adolescents: association with metabolic risk profile. Fertility and Sterility, 2013, 100, 1745-1751.	0.5	29
135	Early detection of liver steatosis by magnetic resonance imaging in rats infused with glucose and Intralipid solutions and correlation to insulin levels. Metabolism: Clinical and Experimental, 2013, 62, 1850-1857.	1.5	17
136	Comparison of contrast-enhanced ultrasonography with grey-scale ultrasonography and contrast-enhanced computed tomography in diagnosing focal fatty liver infiltrations and focal fatty sparing. Advances in Medical Sciences, 2013, 58, 408-418.	0.9	15

#	Article	IF	Citations
137	Nonalcoholic fatty liver disease and its association with metabolic syndrome in the preoperative period in patients undergoing bariatric surgery. Revista Da AssociaĀŠĀ£o MĀ©dica Brasileira (English) Tj ETQqO	O OorgBT /	Ov <b>e</b> rlock 10 T
138	A Comparison of Hepatic Sonographic Features and Histopathologic Diagnosis in Canine Liver Disease: 138 Cases. Journal of Veterinary Internal Medicine, 2013, 27, 806-813.	0.6	31
139	The Importance of Palmitoleic Acid to Adipocyte Insulin Resistance and Whole-Body Insulin Sensitivity in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E40-E50.	1.8	38
140	Sleep duration and quality in relation to non-alcoholic fatty liver disease in middle-aged workers and their spouses. Journal of Hepatology, 2013, 59, 351-357.	1.8	131
141	The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-Year's prospective cohort study. Atherosclerosis, 2013, 227, 398-403.	0.4	33
142	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transplant International, 2013, 26, 67-74.	0.8	58
143	Relationship between Serum Uric Acid Level and Nonalcoholic Fatty Liver Disease in Pre- and Postmenopausal Women. Annals of Nutrition and Metabolism, 2013, 62, 158-163.	1.0	23
145	Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-year prospective cohort study. Hepatology, 2013, 57, 1378-1383.	3.6	140
146	Sonographic hepatorenal ratio: A noninvasive method to diagnose nonalcoholic steatosis. Journal of Clinical Ultrasound, 2013, 41, 18-25.	0.4	53
147	Correlation between liver fat content with dyslipidemia and Insulin resistance. Indian Journal of Endocrinology and Metabolism, 2013, 17, 355.	0.2	4
148	Relationship between Serum Osteocalcin Levels and Non-Alcoholic Fatty Liver Disease in Adult Males, South China. International Journal of Molecular Sciences, 2013, 14, 19782-19791.	1.8	24
149	Sonographic Evaluation for Predicting the Presence and Severity of Coronary Artery Disease. Ultrasound Quarterly, 2013, 29, 125-130.	0.3	13
150	Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography. European Journal of Gastroenterology and Hepatology, 2013, 25, 1330-1334.	0.8	32
151	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. European Journal of Gastroenterology and Hepatology, 2013, 25, 1113-1122.	0.8	15
152	Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Journal of Clinical Pathology, 2013, 66, 1033-1045.	1.0	70
153	Cut-Off Values of Visceral Adiposity to Predict NAFLD in Brazilian Obese Adolescents. Journal of Nutrition and Metabolism, 2013, 2013, 1-8.	0.7	8
154	An epidemiological study of the association of coffee with chronic liver disease. Scottish Medical Journal, 2013, 58, 217-222.	0.7	9
155	The association between non-alcoholic fatty liver disease and carotid atherosclerosis in subjects with within-reference range alanine aminotransferase levels. Endocrine Journal, 2013, 60, 1295-1301.	0.7	7

#	Article	IF	Citations
156	High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocrine Journal, 2013, 60, 743-752.	0.7	76
157	The role of ultrasonography in the measurement of subcutaneous and visceral fat and its correlation with hepatic steatosis. Radiologia Brasileira, 2013, 46, 273-278.	0.3	11
158	Tumor Necrosis Factor- $\hat{l}\pm$ as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. Endocrinology and Metabolism, 2013, 28, 41.	1.3	71
159	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World Journal of Gastroenterology, 2013, 19, 57.	1.4	104
160	Clinical Significance of Non-Alcoholic Fatty Liver Disease as a Risk Factor for Prehypertension. Journal of Korean Medical Science, 2014, 29, 973.	1.1	24
161	Clinical association between nonâ€alcoholic fatty liver disease and the development of hypertension. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1926-1931.	1.4	97
162	A Public Health Issue that Increased Prevelance: Non-Acholic Fatty Liver Disease. TAF Preventive Medicine Bulletin, 2014, 13, 65.	0.1	3
163	Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open, 2014, 4, e004973.	0.8	74
164	The Functional Pitch of an Organ: Quantification of Tissue Texture with Photoacoustic Spectrum Analysis. Radiology, 2014, 271, 248-254.	3.6	83
165	Hepatic steatosis and nonâ€alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. Diabetic Medicine, 2014, 31, 1039-1046.	1.2	19
166	Prerecovery liver biopsy in the brain-dead donor: A case-control study of logistics, safety, precision, and utility. Liver Transplantation, 2014, 20, 237-244.	1.3	6
167	Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease. Scandinavian Journal of Gastroenterology, 2014, 49, 979-985.	0.6	19
168	Fat and Iron Quantification in the Liver. Topics in Magnetic Resonance Imaging, 2014, 23, 73-94.	0.7	43
169	Noninvasive assessment of liver steatosis using ultrasound methods. Medical Ultrasonography, 2014, 16, 236-45.	0.4	43
170	Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgraduate Medical Journal, 2014, 90, 254-266.	0.9	12
171	Detecting hepatic steatosis using ultrasound-induced thermal strain imaging: an <i>ex vivo</i> animal study. Physics in Medicine and Biology, 2014, 59, 881-895.	1.6	16
172	Abdominal MRI at 3.0 T: LAVAâ€flex compared with conventional fat suppression T1â€weighted images. Journal of Magnetic Resonance Imaging, 2014, 40, 58-66.	1.9	34
173	The Role of Ultrasonography in the Evaluation of Diffuse Liver Disease. Radiologic Clinics of North America, 2014, 52, 1163-1175.	0.9	40

#	Article	IF	CITATIONS
174	Ultrasound of the Liver and Spleen. Ultrasound Clinics, 2014, 9, 545-565.	0.2	2
175	Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scandinavian Journal of Gastroenterology, 2014, 49, 611-616.	0.6	31
176	Relationship between serum uric acid levels and hepatic steatosis in non-obese postmenopausal women. Climacteric, 2014, 17, 692-699.	1.1	13
177	Clinical Problem Solving. Journal of Ultrasound in Medicine, 2014, 33, 9-22.	0.8	3
178	Adiponectin is better predictor of subclinical atherosclerosis than liver function tests in patients with nonalcoholic fatty liver disease. Journal of the American Society of Hypertension, 2014, 8, 376-380.	2.3	12
179	Metabolic Health Is More Important than Obesity in the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Retrospective Study. Endocrinology and Metabolism, 2015, 30, 522.	1.3	25
180	MDCT classification of steatotic liver. European Journal of Gastroenterology and Hepatology, 2015, 27, 290-297.	0.8	13
181	Menopausal stages and non-alcoholic fatty liver disease in middle-aged women. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 190, 65-70.	0.5	45
182	Ultrasound-based tissue characterization and classification of fatty liver disease: A screening and diagnostic paradigm. Knowledge-Based Systems, 2015, 75, 66-77.	4.0	62
183	Listen to the chemical and histological information in biological tissue. Chinese Chemical Letters, 2015, 26, 395-400.	4.8	3
184	Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacological Research, 2015, 99, 74-81.	3.1	173
185	Age at menarche and non-alcoholic fatty liver disease. Journal of Hepatology, 2015, 62, 1164-1170.	1.8	48
186	Relationship of sitting time and physical activity with non-alcoholic fatty liver disease. Journal of Hepatology, 2015, 63, 1229-1237.	1.8	160
187	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. European Journal of Pharmacology, 2015, 766, 31-36.	1.7	11
188	Significance of exercise in nonalcoholic fatty liver disease in men: a community-based large cross-sectional study. Journal of Gastroenterology, 2015, 50, 230-237.	2.3	19
189	The prevalence of bright liver echo pattern in patients with chronic hepatitis C: correlation with steatosis and fibrosis. Journal of Ultrasound, 2016, 19, 91-98.	0.7	3
190	The Risk for Insulin Resistance according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men. Journal of Korean Medical Science, 2016, 31, 1761.	1.1	3
191	The Risk of Abdominal Obesity according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men. Journal of Korean Medical Science, 2016, 31, 410.	1.1	12

#	Article	IF	Citations
192	Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. British Journal of Radiology, 2016, 89, 20151024.	1.0	84
193	Carotid intima–media thickness, nonalcoholic fatty liver disease, and hemoglobin A1c are independently associated with the severity of psoriasis. Dermatologica Sinica, 2016, 34, 135-140.	0.2	2
194	Screening for rare variants in the PNPLA3 gene in obese liver biopsy patients. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 715-721.	0.7	3
195	Automated stratification of liver disease in ultrasound: An online accurate feature classification paradigm. Computer Methods and Programs in Biomedicine, 2016, 130, 118-134.	2.6	121
196	Low testosterone and non-alcoholic fatty liver disease: Evidence for their independent association in men with chronic spinal cord injury. Journal of Spinal Cord Medicine, 2016, 39, 443-449.	0.7	56
197	Association study of PNPLA2 gene with histological parameters of NAFLD in an obese population. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 333-339.	0.7	7
198	Effect of metformin treatment on circulating osteoprotegerin in patients with nonalcoholic fatty liver disease. Hepatology International, 2016, 10, 169-174.	1.9	18
199	Type 2 Diabetes., 0,,.		4
200	Cardiorespiratory Fitness and Risk of Fatty Liver. Medicine and Science in Sports and Exercise, 2017, 49, 1834-1841.	0.2	20
201	Low-dose attenuation correction in diagnosis of non-alcoholic fatty liver disease. Abdominal Radiology, 2017, 42, 2454-2459.	1.0	2
202	Association of plasma dipeptidyl peptidase-4 activity with non-alcoholic fatty liver disease in nondiabetic Chinese population. Metabolism: Clinical and Experimental, 2017, 73, 125-134.	1.5	23
203	Differential relationships of hepatic and epicardial fat to body composition in HIV. Physiological Reports, 2017, 5, e13386.	0.7	9
204	The ZJU index is a powerful index for identifying NAFLD in the general Chinese population. Acta Diabetologica, 2017, 54, 905-911.	1.2	23
205	Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. Journal of Nutrition, Health and Aging, 2017, 21, 404-412.	1.5	94
206	Multimaterial Decomposition Algorithm for the Quantification of Liver Fat Content by Using Fast-Kilovolt-Peak Switching Dual-Energy CT: Experimental Validation. Radiology, 2017, 282, 381-389.	3.6	39
207	Is Vitamin D an Independent Risk Factor of Nonalcoholic Fatty Liver Disease?: a Cross-Sectional Study of the Healthy Population. Journal of Korean Medical Science, 2017, 32, 95.	1.1	17
208	Benefits of Levothyroxine Replacement Therapy on Nonalcoholic Fatty Liver Disease in Subclinical Hypothyroidism Patients. International Journal of Endocrinology, 2017, 2017, 1-10.	0.6	45
209	Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in Breast Cancer Patients. Tumori, 2017, 103, 187-192.	0.6	9

#	Article	IF	CITATIONS
210	Association between cotinineâ€verified smoking status and risk of nonalcoholic fatty liver disease. Liver International, 2018, 38, 1487-1494.	1.9	27
211	Prevalence and risk factors of nonâ€alcoholic fatty liver disease in Bangladesh. JGH Open, 2018, 2, 39-46.	0.7	35
212	Single-energy non-contrast hepatic steatosis criteria applied to virtual non-contrast images: is it still highly specific and positively predictive?. Clinical Radiology, 2018, 73, 594.e7-594.e15.	0.5	17
213	Validity of ultrasonography to assess hepatic steatosis compared to magnetic resonance spectroscopy as a criterion method in older adults. PLoS ONE, 2018, 13, e0207923.	1.1	17
214	Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surgery for Obesity and Related Diseases, 2018, 14, 1607-1616.	1.0	56
215	Correlation between Non-Alcoholic Fatty Liver Disease and Visceral Adipose Tissue in Non-Obese Chinese Adults: A CT Evaluation. Korean Journal of Radiology, 2018, 19, 923.	1.5	30
216	Working hours and nonalcoholic fatty liver disease according to sleep duration. Chronobiology International, 2019, 36, 1671-1680.	0.9	9
217	Additional fibrate treatment in UDCAâ€refractory PBC patients. Liver International, 2019, 39, 1776-1785.	1.9	24
218	Effectiveness of two physical activity programs on non-alcoholic fatty liver disease. a randomized controlled clinical trial. Revista De La Facultad De Ciencias Medicas De Cordoba, 2019, 76, 26.	0.1	18
219	Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. Atherosclerosis, 2019, 284, 59-65.	0.4	15
220	Circulating Hsp90 Isoform Levels in Overweight and Obese Children and the Relation to Nonalcoholic Fatty Liver Disease: Results from a Cross-Sectional Study. Disease Markers, 2019, 2019, 1-6.	0.6	15
221	Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 1065-1069.	1.8	26
222	Childhood Socioeconomic Disadvantage and Risk of Fatty Liver in Adulthood: The Cardiovascular Risk in Young Finns Study. Hepatology, 2020, 71, 67-75.	3.6	9
223	Evaluation of the liver with virtual non-contrast: single institution study in 149 patients undergoing TAVR planning. British Journal of Radiology, 2020, 93, 20190701.	1.0	11
224	Radiologic Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Suppressed Chronic Hepatitis B. Journal of Clinical Gastroenterology, 2020, 54, 633-641.	1.1	20
225	Ultrasound-based Classification of Fatty Liver Disease: A Review. Journal of Physics: Conference Series, 2020, 1531, 012033.	0.3	3
226	Correlation between computed tomography adapted leaman score and computed tomography liver and spleen attenuation parameters for non-alcoholic fatty liver disease as well as respective inflammatory mediators. International Journal of Cardiovascular Imaging, 2020, 36, 2383-2391.	0.7	2
227	Effects of Prunus cerasus L. Seeds and Juice on Liver Steatosis in an Animal Model of Diet-Induced Obesity. Nutrients, 2020, 12, 1308.	1.7	15

#	Article	IF	CITATIONS
228	Multiâ€energy computed tomography and material quantification: Current barriers and opportunities for advancement. Medical Physics, 2020, 47, 3752-3771.	1.6	14
229	<p>Common and Unique Factors and the Bidirectional Relationship Between Chronic Kidney Disease and Nonalcoholic Fatty Liver in Type 2 Diabetes Patients</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1203-1214.	1.1	12
230	Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. International Journal of Medical Sciences, 2020, 17, 182-190.	1.1	33
231	Diagnosis of hepatic lipidosis in a tiger salamander (Ambystoma tigrinum) by computed tomography. Journal of Exotic Pet Medicine, 2020, 33, 18-22.	0.2	2
232	lodine accumulation of the liver in patients treated with amiodarone can be unmasked using material decomposition from multiphase spectral-detector CT. Scientific Reports, 2020, 10, 6994.	1.6	2
233	Childhood and Adulthood Passive Smoking and Nonalcoholic Fatty Liver in Midlife: A 31-year Cohort Study. American Journal of Gastroenterology, 2021, 116, 1256-1263.	0.2	11
234	A comprehensive review of long non-coding RNAs in the pathogenesis and development of non-alcoholic fatty liver disease. Nutrition and Metabolism, 2021, 18, 22.	1.3	31
235	Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method. Medical Ultrasonography, 2021, 23, 7.	0.4	17
236	Impact of hepatic steatosis on outcomes after left ventricular assist device implantation. Journal of Cardiac Surgery, 2021, 36, 2277-2283.	0.3	0
237	Non-invasive Assessment of Liver Fat in ob/ob Mice Using Ultrasound-Induced Thermal Strain Imaging and Its Correlation with Hepatic Triglyceride Content. Ultrasound in Medicine and Biology, 2021, 47, 1067-1076.	0.7	0
238	Nonalcoholic fatty liver disease is a risk factor for glucose intolerance onset in men regardless of alanine aminotransferase status. Journal of Diabetes Investigation, 2021, 12, 1890-1898.	1.1	2
239	Hypothyroidism and Non-alcoholic Fatty Liver Disease: Association and Effect of Levothyroxine Replacement Therapy. The Egyptian Family Medicine Journal, 2021, 5, 52-67.	0.2	0
240	Characterizing the aggressiveness of prostate cancer using an all-optical needle photoacoustic sensing probe: feasibility study. Biomedical Optics Express, 2021, 12, 4873.	1.5	3
241	A comparison of liver fat fraction measurement on MRI at 3T and 1.5T. PLoS ONE, 2021, 16, e0252928.	1.1	2
242	Evaluation of Adjuvant Chemotherapy-Associated Steatosis (CAS) in Colorectal Cancer. Current Oncology, 2021, 28, 3030-3040.	0.9	2
243	Association between Nonalcoholic Fatty Liver Disease and Bone Mineral Density in HIV-Infected Patients Receiving Long-term TDF-Based Antiretroviral Therapy. Current HIV Research, 2021, 19, 40-46.	0.2	2
244	Visualization of quantitative lipid distribution in mouse liver through near-infrared hyperspectral imaging. Biomedical Optics Express, 2021, 12, 823.	1.5	12
245	Traditional Markers in Liver Disease. Biomarkers in Disease, 2017, , 3-22.	0.0	1

#	Article	IF	CITATIONS
246	Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease. Medical Ultrasonography, 2015, 17, 300.	0.4	31
247	Waist Gain Is Associated with a Higher Incidence of Nonalcoholic Fatty Liver Disease in Korean Adults: A Cohort Study. PLoS ONE, 2016, 11, e0158710.	1.1	13
248	Doen $\tilde{A}$ sa hep $\tilde{A}_i$ tica gordurosa n $\tilde{A}$ £o alco $\tilde{A}$ 3lica em escolares obesos. Revista Paulista De Pediatria, 2008, 26, 136-141.	0.4	6
249	Retinol binding protein-4 as a serum biomarker of intrahepatic lipid content in obese children-preliminary report Acta Biochimica Polonica, 2011, 58, .	0.3	13
250	Correlation between bright echogenic liver, elevated liver enzymes and liver histology. Journal of Dhaka National Medical College & Hospital, 2012, 17, 8-13.	0.2	2
252	Nonalcoholic fatty liver disease: An overview of current insights in pathogenesis, diagnosis and treatment. World Journal of Gastroenterology, 2008, 14, 2474.	1.4	158
253	Non-invasive means of measuring hepatic fat content. World Journal of Gastroenterology, 2008, 14, 3476.	1.4	226
254	Sonographic fatty liver and hepatitis B virus carrier status: Synergistic effect on liver damage in Taiwanese adults. World Journal of Gastroenterology, 2007, 13, 1805.	1.4	20
255	Correlation of fatty liver and abdominal fat distribution using a simple fat computed tomography protocol. World Journal of Gastroenterology, 2011, 17, 3335.	1.4	19
256	Association between serum alpha-fetoprotein levels and fatty liver disease: A cross-sectional study. World Journal of Gastroenterology, 2014, 20, 11865.	1.4	16
257	Prevalence of asymptomatic nonalcoholic fatty liver disease in nondiabetic participants: a study from south india. The Egyptian Journal of Internal Medicine, 2019, 31, 92-98.	0.3	4
258	Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. Journal of Medical Ultrasound, 2019, 27, 19-25.	0.2	10
259	Non Alcoholic Fatty Liver Overview. Journal of Liver, 2015, 04, .	0.3	1
260	Serum Uric Acid as a Predictor for the Development of Nonalcoholic Fatty Liver Disease in Apparently Healthy Subjects: A 5-Year Retrospective Cohort Study. Gut and Liver, 2010, 4, 378-383.	1.4	77
261	Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iranian Red Crescent Medical Journal, 2014, 16, e12669.	0.5	20
262	Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity. â€â€«â€¬â€Thrita Journal of Medical Sciences, 2013, 2, 43-51.	0.2	6
263	Accuracy of Multi-echo Dixon Sequence in Quantification of Hepatic Steatosis. Cureus, 2020, 12, e7103.	0.2	4
264	Synergistic Interaction of Dietary Pattern and Concordance Lifestyle with Abnormal Liver Function among Young Adults in Taiwan: A Population-Based Longitudinal Study. Nutrients, 2021, 13, 3591.	1.7	3

#	Article	IF	CITATIONS
265	Increases Over the Past 10 Years in Fatty Liver, Non-alcoholic Fatty Liver and Suspicious Non-alcoholic Steatohepatitis as Seen in Ultra-sound Examinations Attending General Health Check-ups. Health Evaluation and Promotion, 2006, 33, 495-501.	0.0	3
266	Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. , 2007, , 553-560.		0
267	Ultrasonography. , 2010, , 359-404.		0
268	Ultrasound in the diagnostics of fatty liver in obesity. Orvosi Hetilap, 2011, 5, 119-125.	0.2	0
269	Metabolic Steatosis & Fibrosis: Review of the Non-Invasive Tools for Diagnosis and Screening. , 0, , .		0
270	Inflammation and Hypoglycemia: The Lipid Connection. , 0, , .		0
271	The Liver in Metabolic Syndrome. , 2014, , 27-61.		1
272	The Effects of Thyroid Dysfunctions on Insulin Resistance in Patients with Hepatosteatosis. Advances in Clinical and Experimental Medicine, 2014, 23, 913-918.	0.6	1
273	Computerized ultrasound image analysis for noninvasive evaluation of hepatic steatosis. Medical Ultrasonography, 2015, 17, 431-6.	0.4	3
274	The Use of Computed Tomography in the Diagnosis of Fatty Liver and Abdominal Fat Distribution among a Saudi Population. Open Access Macedonian Journal of Medical Sciences, 2017, 5, 762-765.	0.1	2
275	Epidemiology, Natural History, and Evaluation of Nonalcoholic Fatty Liver Disease., 2018,, 391-405.e3.		1
276	Hepatic steatosis and fibrosis: evaluation with CT imaging. Acta Hepatologica Japonica, 2018, 59, 393-406.	0.0	1
277	Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease. Journal of Clinical Medicine, 2021, 10, 5194.	1.0	8
278	Nonalkolik hepatosteatozda portal ven pulsatilite indeksi hepatik arter rezistif indeksi ile karaciÄŸer fibrozisi ¶ng¶r¼s¼ i§in bir prediktif parametre olarak kullanılabilir mi?. Acta Medica Alanya, 0, , 19-20.	0.2	0
279	Assessment of NAFLD cases and its correlation to BMI and metabolic syndrome in healthy blood donors in Kerman. Gastroenterology and Hepatology From Bed To Bench, 2012, 5, 183-9.	0.6	2
280	Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis. Nutrition and Diabetes, 2022, 12, 4.	1.5	9
281	Evaluation of a Whole-Liver Dixon-Based MRI Approach for Quantification of Liver Fat in Patients with Type 2 Diabetes Treated with Two Isocaloric Different Diets. Diagnostics, 2022, 12, 514.	1.3	2
282	Fatty liver with metabolic disorder, such as metabolic dysfunctionâ€associated fatty liver disease, indicates high risk for developing diabetes mellitus. Journal of Diabetes Investigation, 2022, 13, 1245-1252.	1.1	6

#	Article	IF	CITATIONS
284	Combined evaluation of Fibrosisâ€4 index and fatty liver for stratifying the risk for diabetes mellitus. Journal of Diabetes Investigation, 2022, , .	1.1	0
286	Anxiety and Depression in Metabolic-Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk. Journal of Clinical Medicine, 2022, 11, 2488.	1.0	1
287	MBOAT7 rs641738 variant in metabolic-dysfunction-associated fatty liver disease and cardiovascular risk. Medicine and Pharmacy Reports, 0, , .	0.2	0
288	Liver–Spleen Ratio: Can It Be Used for the Prediction of Coronary Artery Disease?. , 2022, 26, 762-770.		2
289	Subclinical hypothyroidism in obese Turkish adolescents: the relationship with anthropometry and fatty liver. Turkish Journal of Medical Sciences, $0$ , , .	0.4	4
290	Ultrasonographically detected hepatosteatosis independently predicts the presence and severity of coronary artery disease. African Health Sciences, 2022, 22, 273-285.	0.3	1
291	The association of nonalcoholic fatty liver disease with bone mineral density in type 2 diabetes. European Journal of Medical Research, 2022, 27, .	0.9	1
292	Speed of sound index for liver steatosis estimation: a reliability study in normal subjects. , 2022, 28, 418-427.		0
293	Measurement and Modeling of the Optical Properties of Adipose Tissue in the Terahertz Range: Aspects of Disease Diagnosis. Diagnostics, 2022, 12, 2395.	1.3	1
294	The role of ultrasonographic hepatic artery resistive index in the diagnosis of insulin resistance in obese children with non-alcoholic fatty liver disease. Turkish Journal of Medical Sciences, 0, , .	0.4	2
295	CGMap: Characterizing continuous glucose monitor data in thousands of non-diabetic individuals. Cell Metabolism, 2023, 35, 758-769.e3.	7.2	6